Allard v. Canada

Allard v. Canada
Court (s) Database
Federal Court Decisions
Date
2014-03-21
Neutral citation
2014 FC 280
File numbers
T-2030-13
Notes
A correction was made on May 13, 2014
Decision Content
Date: 20140321
Docket:
T-2030-13
Citation: 2014 FC 280
Vancouver, British Columbia, March 21, 2014
PRESENT: The Honourable Mr. Justice Manson
BETWEEN:
NEIL ALLARD
TANYA BEEMISH
DAVID HEBERT
SHAWN DAVEY
Applicants/Plaintiffs
and
HER MAJESTY THE QUEEN
IN RIGHT OF CANADA
Respondent/Defendant
REASONS FOR ORDER AND ORDER
INTRODUCTION
[1] This is a motion for an interlocutory injunction or an interlocutory constitutional exemption together with an order in the nature of mandamus pursuant to subsection 24(1) of the Canadian Charter of Rights and Freedoms, Part 1 of the Constitution Act, 1982, being Schedule B to the Canada Act 1982 (UK), 1982, c 11 [the Charter], and Rule 373(1) of the Federal Court Rules [the Rules]. The moving parties [the Applicants] are the Plaintiffs in this action.
[2] The action underlying the motion at issue is for various declarations pursuant to subsections 24(1) and 52(1) of the Charter. The declarations sought rely on section 7 of the Charter to invalidate recent changes to a regulatory scheme enacted by the federal government, which dictate the circumstances in which medically-approved patients may obtain and possess marihuana. These changes, contained in the Marihuana for Medical Purposes Regulations, SOR/2013-119 [the MMPR], repeal the Marihuana Medical Access Regulations, SOR/2001-227 [the MMAR] in their entirety by March 31, 2014.
[3] The relief sought by the Applicants would preserve the provisions of the MMAR and limit the applicability of certain provisions of the MMPR, pending a final resolution of the merits of their claims. This motion was filed with the Court on January 31, 2014.
[4] For the reasons that follow, I grant limited relief to the Applicants by preserving certain rights under the MMAR as of September 30, 2013. The motion is otherwise dismissed.
A. Legislative Scheme
I. Introduction
[5] The requirement of the government to provide reasonable access to marihuana for medical purposes was recognized by R v Parker, [2000] OJ No 2787 (CA) [Parker] and affirmed in R v Mernagh, 2013 ONCA 67, among others. In brief, Parker held that a failure to provide a viable medical exemption from the provisions of the Controlled Drugs and Substances Act, SC 1996, c 19 [CDSA] violated the liberty and security of the person guarantees under section 7 of the Charter, in a manner that was inconsistent with the principles of fundamental justice, by forcing certain individuals to choose between their liberty and their health. This direction from the Ontario Court of Appeal led first to exemptions from the CDSA pursuant to section 56 of that act, and then to the establishment of the MMAR.
[6] Today, the consumption and distribution of medical marihuana in Canada is governed by three sets of regulations: the Narcotic Control Regulations, CRC, c 1041 [the NCR], the MMAR and the MMPR. The NCR allows medical practitioners to prescribe marihuana despite the provisions of the CDSA. The MMAR was, until June 6, 2013, the primary regulatory mechanism which dictated the circumstances under which this exemption can be exercised. As of June 6, 2013, the MMPR began to take effect. These regulations made changes to the NCR and the MMAR and will run concurrent with the MMAR until March 31, 2014, when the MMAR is scheduled to be repealed in its entirety.
II. Narcotic Control Regulations
[7] As of the changes made by the MMPR on June 6, 2013, subsection 53(5) of the NCR provides that a medical practitioner may prescribe, transfer or administer dried marihuana to a person under their professional treatment if that dried marihuana is required for the condition being treated.
[8] Prior to June 6, 2013, section 53 of the NCR was not limited to “dried” marihuana.
III. Marihuana Medical Access Regulations
[9] While portions of the MMPR have taken effect, the MMAR is effectively the current regulatory regime for possession and production of marihuana for medicinal uses. As of March 31, 2014, it will be repealed in its entirety.
[10] The MMAR provides for a licence scheme whereby eligible persons who are prescribed marihuana by a medical practitioner are issued an Authorization to Possess [ATP] marihuana pursuant to section 11. A valid ATP authorizes the holder to possess up to 30 times the amount of marihuana they are prescribed to consume daily.
[11] The MMAR also provides for three ways by which a person may obtain marihuana. Two are relevant to this motion. They may either produce marihuana themselves under a Personal-use Production Licence [PPL], pursuant to section 24, or have a designated person produce marihuana for them under a Designated-person Production Licence [DPL], pursuant to section 34. These licences dictate both the maximum number of plants that can be grown simultaneously and the maximum quantity of dried marihuana that can be stored on a production site at any time.
[12] Production of marihuana in accordance with a PPL or DPL must be conducted only on the site designated on that PPL or DPL. This site may be indoors or outdoors, but not both simultaneously. There are no restrictions as to the location of the production facility beyond the fact that if outdoors, it must not be adjacent to a school, public playground, daycare facility or other public place frequented mainly by persons less than 18 years of age. Production in a dwelling-place is allowed.
[13] On June 7, 2013, the MMAR was amended to prohibit the issuance of PPLs and DPLs after September 30, 2013, unless the application for such a licence was received prior to September 30, 2013. This amendment was made in anticipation of the regulatory changes brought by the MMPR.
IV. Marihuana for Medical Purposes Regulations
[14] The MMPR makes substantial changes to the production scheme for medical marihuana in Canada. Notably, all PPLs and DPLs are no longer valid as of the repeal of the MMAR, and the amount that an individual is authorized to posses may be lowered in some cases.
[15] The MMPR mandates that dried marihuana be produced by a Licensed Producer [LP], pursuant to section 12 of the MMPR. Individuals who formerly were or could be issued an ATP must register the prescription of a medical practitioner with an LP to obtain dried marihuana. If they do so, section 3 authorizes them to obtain and possess marihuana produced by that LP. The amount authorized for possession under section 5 is lower than under the MMAR: either 150 grams or 30 times the amount prescribed for daily consumption by the individual’s medical practitioner, whichever is less.
[16] An LP is required to meet various quality and security measures as per sections 12-101. This includes provisions in sections 13 and 14 which state that the production site may not be outdoors or in a dwelling-place.
B. The Applicants
[17] The Applicants all hold or held an ATP and/or a PPL or DPL. Their affidavits outline their concerns that the repeal of the MMAR and the regulatory changes introduced in the MMPR will bring them increased costs and decrease the safety and quality of the marihuana they consume.
I. Neil Allard
[18] Mr. Allard is 59 years of age and is a resident of Nanaimo, British Columbia. He was employed as a counsellor with Veteran’s Affairs Canada until 1995, when myalgic encephalomyelitis (commonly known as Chronic Fatigue Syndrome) [CFS] caused him to leave work. He was granted permanent medical retirement in 1999 and has been living on a combination of pensions since that time. These pensions currently provide him with a net income of $2,700 per month. At age 65 his income will drop to $2,000 per month.
[19] Mr. Allard states that he began using marihuana to treat his CFS symptoms after he realized he was sensitive to pharmaceutical medication. In 1998, he was referred to the British Columbia Compassion Club Society with a note of support from his physician. By 2001 it cost him approximately $500 per month to obtain marihuana through the Society. As a result of this cost, he took steps to obtain an ATP and a PPL. He currently holds a PPL to produce up to 98 plants and store 4,410 grams indoors. He also holds an ATP which authorizes him to possess up to 600 grams on his person at any time. Both expire on March 31, 2014.
[20] In 2004, he received his first PPL and began cultivating marihuana at his residence. Since that time he has moved twice and claims to have spent thousands of dollars to renovate his current basement to accommodate the cultivation of marihuana indoors. This included professional wiring, insulation, venting, painting, plumbing and the purchase of growing equipment to facilitate the production of marihuana. In addition, he has purchased motion detectors, carbon dioxide and smoke alarms, and has a tall fence at his property line.
[21] Mr. Allard ingests his marihuana through various means. Based on his current means of production, this rate of consumption costs approximately $200-$300 per month. In addition, he estimates that the financial cost of setting up the production sites at his three residences to be approximately $35,000.
[22] Mr. Allard estimates that to maintain his current dosage through an LP at a cost of $8-10 per gram would cost approximately $6,000 per month, and $3,000 at a cost of $5 per gram. In either event, it is more than his monthly income either now or upon his retirement, and these costs are not eligible for assistance under any health care plan. Given these increased costs, Mr. Allard fears that he may have to risk imprisonment by continuing to produce marihuana or procuring it through the illicit market.
[23] Mr. Allard further notes that he has been able to identify strains of marihuana which are specific to his medical needs and continues to experiment with other strains that alleviate his symptoms in an effective way, as some strains exacerbate his symptoms. He states that the strains he requires may not be available through an LP, and if he needed to resort to the black market, he would have no guarantees as to the quality or safety of the product.
II. Tanya Beemish and David Hebert
[24] Ms. Beemish and Mr. Hebert are a common law couple who reside in Surrey, British Columbia. Ms. Beemish is 27 years old and Mr. Hebert is 32. Ms. Beemish was employed as a barista until June, 2012, when she went on sick leave. Since December, 2012, she has received a Canada Pension Plan disability pension of $596.73 monthly. She suffers from type one diabetes and gastroparesis.
[25] On January 4, 2013, Ms. Beemish received an ATP to alleviate her symptoms of extreme nausea, vomiting, pain, lack of appetite, and insomnia. She uses a daily dose of 2-10 grams which she ingests via smoking or vaporizing. Her ATP, which authorized her to possess 150 grams, expired on January 4, 2014.
[26] Mr. Hebert is the Health Canada approved designated grower for Ms. Beemish. He is employed as an Environmental Protection Officer. His DPL allowed him to produce 25 plants indoors and store 1125 grams of marihuana at the production site. He produced the marihuana for Ms. Beemish in a secure room attached to their townhouse garage, which was ventilated, and had mold controls and fire alarms. While his DPL expired on January 4, 2014, he was unable to legally produce marihuana as of October 30, 2013, when he moved residences and was unable to renew his DPL.
[27] Mr. Hebert estimates that the cost to produce the marihuana was approximately $0.50 per gram, exclusive of capital costs to create his production facility. Both Mr. Hebert and Ms. Beemish state that costs of $8-12 dollars for marihuana produced by an LP is beyond what is affordable, noting that even a cost of $5 per gram is a tenfold increase in what it costs Mr. Hebert to produce marihuana for Ms. Beemish. They fear that they will have to turn to the black market to find affordable marihuana, with no guarantees as to the quality and safety of the product.
III. Shawn Davey
[28] Mr. Davey is 37 years old and resides in Abbotsford, British Columbia. Mr. Davey was employed building custom vehicles until June 16, 2000, when he was involved in a motor vehicle accident in which he suffered a serious brain injury. As a result of an insurance settlement and his Canada Pension Plan Disability pension, his monthly income is approximately $5,000.
[29] Following his accident, Mr. Davey was prescribed various medications for the next six years to deal with chronic pain as a result of his accident. These medications cost him $3,000 per month. He began using marihuana and found it effectively dealt with his symptoms and allowed him to stop using other medications. Starting in 2007, he began receiving marihuana through a designated grower. However, this grower was unable to consistently provide a safe supply of high quality. After switching designated growers and encountering similar problems, he decided to produce his own marihuana. He currently possesses an ATP, which authorizes him to possess 750 grams at any time. He also possess a PPL, which authorizes him to produce 122 plants indoors and store 5,490 grams at the site of production. These licences expire on March 31, 2014.
[30] His production facility is on an outbuilding on his property. He can produce his marihuana at a cost between $1 and $2 per gram, and he uses approximately 25 grams per day, for a cost of between $750 and $1,500 per month, less than the $3,000 he spent on pharmaceutical medications prior to when he began using medical marihuana.
[31] Mr. Davey is concerned about the effectiveness and quality of the marihuana produced by an LP, given his negative experience with previous designated growers and because his marihuana needs require a 12-18% tetrahydrocannabinol [THC] content to alleviate his symptoms. He also is worried about the increased cost, given that, at his current rate of consumption, he would consume approximately $6,000 per month at a price of $8 per gram. He worries about having to resort to the black market as a result of these regulatory changes.
C. Supporting Affidavit Evidence
I. Applicants’ Supporting Affidavits
(1) Zachary Walsh
[32] Dr. Walsh is an Assistant Professor in the Department of Psychology at the University of British Columbia.
[33] Dr. Walsh details his research relating to access to and reasons for the therapeutic use of marihuana in Canada. He includes two articles that he has prepared for the International Journal of Drug Policy; one published, and one awaiting publication.
[34] Dr. Walsh notes that approximately 1 million Canadians reported using marihuana to treat self-defined medical conditions. However, as of December, 2012, only 28,115 Canadians had a valid ATP.
[35] Dr. Walsh also refers to research showing that more than half of respondents in studies stated that financial considerations impacted whether they were able to buy a sufficient amount of marihuana to address their therapeutic needs. For example, 54% of respondents reported they were sometimes, or never, able to afford to buy sufficient quantities of marihuana to relieve their symptoms. Approximately one-third reported that they often or always choose between marihuana and other necessities, such as food or other medicines, because of a lack of money. In his opinion, this demonstrates that the affordability of marihuana for therapeutic purposes remains a significant barrier for many Canadians and especially the most seriously ill.
[36] Dr. Walsh concludes by arguing that the MMPR, even by the government’s cost-benefit analysis, will involve a significant price increase which will impact the ability of patients to obtain marihuana for therapeutic purposes.
(2) Susan Boyd
[37] Dr. Susan Boyd is a Professor in the Faculty of Human and Social Development at the University of Victoria. Her areas of study include drug law and policy, and she is the co-author of the book “Killer Weed: Marihuana Grow Ops, Media and Justice.”
[38] Dr. Boyd notes that the overall crime rate in 2010 has fallen in both its volume and severity since the 1970s. She also criticizes a review study by Darryl Plecas of the University of the Fraser Valley [Plecas report]. She notes that while that report purports to link grow operations with violence, 89% of the grow operations referred to did not have firearms or other weapons or hazards present. Only 6% had firearms on site – only slightly higher than the 5.5% of the Canadian population who hold such licences.
[39] Dr. Boyd also criticizes the risk of fire from indoor marihuana grow operations as stated in the Plecas report. She claims that the proportion of fires relating to grow operations was exaggerated. In contrast to the 3.5% in 2001, 3.7% in 2002, and 4.7% in 2003, only 1.21%, 1.02% and 1.3%, respectively, were reported in the Annual Statistical Fire Report. Similarly, the Plecas report’s claims about the dangers in booby-trapped grow operations were exaggerated: only 2.1% of grow operations contained such hazards.
[40] Dr. Boyd argues that safety of PPL and DPL sites can be corrected by having better guidelines, education and monitoring of marihuana production facilities, something that Health Canada has failed to do.
[41] Dr. Boyd concludes that newspaper coverage has created a persistent link between mold, fire and other property damage in a way that is not supported by any statistical reality.
II. Respondent’s Supporting Affidavits
(1) Cpl. Shane Holmquist
[42] Corporal Holmquist (acting) has been a member of the RCMP since April, 2005. He is seconded to the Federal Serious Organized Crime Section on the Coordinated Marihuana Enforcement Team, which investigates marihuana grow operations, among other tasks. He has also provided training to Health Canada Inspectors, Drug Investigators in Canada, and law enforcement personnel in the United States regarding the production and trafficking of marihuana. In addition, he is the Provincial RCMP MMPR Coordinator for British Columbia, which involves him in the application process for approving LPs.
[43] Cpl. Holmquist noted that as of October, 2013, there were 25,809 PPLs and 4,231 DPLs validly held in Canada.
[44] Cpl. Holmquist has attended numerous MMAR grow operations where “monster plants” are grown and more marihuana is produced than the licences allow. While this excess marihuana is supposed to be destroyed, Cpl. Holmquist expressed his opinion that this rarely happens.
[45] He also has seen that MMAR licences are used to disguise commercial-scale grow-operations. He gave an example from 2013, when he discovered a barn which had a licence under the MMAR, but 25 individuals were involved in packaging marihuana in preparation for trafficking. He supports this example with reference to an April, 2009, RCMP Criminal Intelligence Brief entitled “A Review of Cases Related to the Medical Marihuana Access Regulations,” which found 70 licensing violations and 40 instances where those violations involved trafficking excess marihuana for profit. He opines that the sale of excess marihuana is necessitated by the high cost of electricity that the indoor production of marihuana entails. Cpl. Holmquist suggests that selling this excess marihuana often involves collaboration with organized crime.
[46] Cpl. Holmquist also expresses concerns about the terms of an individual’s ATP. In particular, he notes that trafficking may be facilitated by the fact that an ATP can authorize a 30-day supply of marihuana on the holder’s person. This can effectively shield a trafficker, holding a valid ATP, from police scrutiny.
[47] With regard to health and safety, Cpl. Holmquist has witnessed the presence of mold and other chemical contaminations at marihuana grow operations. Further, he notes that a residence which includes a marihuana grow operation has a 24 times greater risk of a fire than one without, given the extensive lighting systems needed to grow marihuana indoors, the use of carbon dioxide generators, and the extraction process involved in producing marihuana oil. Because of the concealed and controlled nature of many grow operations, it makes it difficult for individuals to escape in the event of fire, or for emergency workers to adequately and safely respond in the event of an emergency. He also notes that injuries can occur to marihuana growers from touching lighting systems and slipping on excess water.
[48] Cpl. Holmquist pointed to an RCMP Criminal Intelligence Brief entitled “Marihuana Grow Operations and Related Violence in Canada,” dated April, 2012, which states that “grow-rips,” or theft of medical marihuana, is becoming increasingly common. These grow-rips often are violent and involve the use of weapons. To prevent grow-rips, growers may arm themselves, thereby increasing the risk of injury to bystanders.
[49] Cpl. Holmquist also gives his opinion that various marihuana-products, such as marihuana-infused candy suckers, could be ingested by children living at a grow operation location.
[50] Cpl. Holmquist contrasts the above with his experience being involved with MMPR applications, which have strict growing, security, and packaging standards that serve to address his concerns with the MMAR.
(2) Paul Grootendorst
[51] Dr. Grootendorst is an Associate Professor in the Faculty of Pharmacy at the University of Toronto. His research focuses on health economics. He has provided an expert report with respect to projected marketplace trends under the MMPR and the impacts on LPs if medical marihuana users were not required to purchase medical marihuana from an LP or Health Canada.
[52] Dr. Grootendorst’s opinion with respect to the first issue is that the price of legal, commercially-sourced medical marihuana will decline over time, so long as the market of users grows sufficiently large over time. Dr. Grootendorst opines that it will.
[53] With regard to the second issue, Dr. Grootendorst opines that if medical marihuana users are exempt from the requirement to purchase their marihuana from LPs or Health Canada, then the size of the medical marihuana market will be smaller. He hypothesizes that three possible scenarios will result. The first is that prices of marihuana will decline, but at a slower rate than they would if users were required to buy from LPs. The second is that prices of medical marihuana will increase over time. The third is that eventually no LPs will exist to produce medical marihuana. Dr. Grootendorst does not express an opinion as to the likelihood of these three scenarios.
(3) Jeannine Ritchot
[54] Ms. Ritchot is the former Director of Medical Marihuana Regulatory Reform from 2011-2013 at Health Canada. Prior to that, she was the Director of the Bureau of Medical Cannabis, Office of Controlled Substances, Controlled Substances and Tobacco Directorate, at Health Canada from 2010-2011. Through these positions she oversaw the administration of the MMAR and conducted policy development of the MMPR.
[55] Ms. Ritchot notes that the goals of the MMAR regime were to strike a balance between providing legal access to marihuana for medical purposes while controlling access to a controlled substance, to respect existing federal legislation such as the CDSA, and to protect the individual and public health, security and safety of all Canadians. She opines that the rapid expansion of those licensed to possess marihuana under the MMAR, from 477 in 2002 to 37,884 in January, 2014, has compromised the initial goals of the program. In addition, she notes that as of December 3, 2013, the average number of plants licensed for indoor growth was 101, the average number of plants licensed for outdoor growth was 11, and the average daily dosage is 17.7 grams per day. Despite this, the average amount of marihuana used by those being supplied by Health Canada was between 1 and 3 grams.
[56] Some of the consequences of the rapid expansion of the program has meant that a large amount of marihuana is being produced in private residences and that Health Canada does not have the resources necessary to conduct compliance and enforcement activities. In addition, Health Canada’s program to supply marihuana to patients cost $16.8 million for the three years ending on March 31, 2013. Finally, Health Canada has received solicited and unsolicited feedback from municipalities and first responders, homeowners, and program participants about unanticipated problems with the MMAR regime. These include violence, presence of firearms, diversion to the illicit market, production over the limits authorized, the presence of mold, fire and electrical hazards, toxic chemicals, the emission of noxious odours, and various risks to children living in or near the residential growing operations.
[57] Ms. Ritchot also describes the consultations which took place with regard to the MMPR and in particular, law enforcement representatives who submitted feedback were unanimous that the use of PPLs and DPLs should be discontinued.
[58] Ms. Ritchot describes the purposes of the new MMPR as including: increasing individual and public health, safety and security; treating marihuana as much like other medicinal drugs as possible; facilitating access to multiple strains; returning Health Canada to its traditional role as regulator; and creating a stricter regulated business environment for the production of marihuana.
(4) Todd Cain
[59] Mr. Cain is the Executive Director of Market Development for the Healthy Environments and Consumer Safety Branch of Health Canada. His responsibilities include supporting the transition from the MMAR to the MMPR and resolving issues in the development of a stable supply base for medical marihuana by LPs.
[60] Mr. Cain states that as part of the transition strategy to the MMPR, Health Canada has been developing means by which a stable and continuous supply of marihuana can be assured. One of the key mechanisms to do so has been a publicity campaign to encourage applications from potential LPs. This included partnerships with the private sector, such as the Ontario Greenhouse Vegetable Growers, Flowers Canada Growers, and various provinces and other federal government ministries. This strategy also included preparing guidance documents for the application process and operating a call centre for staff to answer questions from potential applicants.
[61] Mr. Cain notes that as of February 4, 2014, Health Canada has received 454 LP applications, 8 of which have been issued, 10 have been withdrawn, 24 have been refused, and the rest are in various stages of review or screening. Mr. Cain estimates that approximately 25 new applications are received each week.
[62] As of January 30, 2014, six of the eight approved LPs are ready to register clients. Mr. Cain indicates that the prices range from $5 to $12 per gram, and a number of LPs are offering discounts to as low as $3.00 per gram for low income users. Mr. Cain indicates that LPs have stated that approximately 850kg of marihuana will be available for medicinal use as of March 31, 2014. In addition, Health Canada has stockpiled between 400-500kg of marihuana from its previous production facility, and has approved import from the Netherlands of over 100kg of marihuana in the case of supply shortfalls. Mr. Cain also indicates that Health Canada took steps to forecast consumer demand in a manner that was risk-adjusted for unforeseen circumstances.
[63] Based on these forecasts and the steps taken to manage supply and demand, Mr. Cain states that Health Canada has taken significant steps to ensure reasonable access to quality dried marihuana through the transition period and into the future.
D. Relief Sought at Trial
[64] The relief sought by the Applicants at trial can be summarized as follows:
1. A declaration pursuant to subsection 52(1) of the Charter that a constitutionally viable exemption to enable the medical use, by medically approved persons, of cannabis, in any of its effective forms, includes the right of the patient (or a person designated as responsible for the patient), to not only possess and use Cannabis in any of its forms, but also to cultivate or produce and possess Cannabis in any form that is effective for the treatment of the patient’s medical condition.
2. A declaration pursuant to subsection 52(1) of the Charter that the MMPR is unconstitutional only to the extent that it unreasonably restricts the section 7 Charter rights of a medically approved patient to reasonable access to their medicine by way of a safe and continuous supply, by failing to allow for continued personal or designated production of marihuana, and cannot be saved by section 1.
3. Constitutional declarations pursuant to subsection 52(1) that would address the limitations:
A. On “dried” marihuana in the NCR, MMAR and MMPR;
B. The prohibitions on LPs from producing outdoors or in a dwelling-house; and
C. The 150 gram maximum on the amount a patient may possess and an LP may ship.
4. An Order under subsection 24(1) of the Charter granting a permanent injunction or a permanent constitutional exemption of the same form sought in the interim in this motion, which is described below.
ORDER REQUESTED
[65] An Order under section 24(1) of the Charter is sought in the nature of:
1. An interim constitutional exemption from ss.4, 5 and 7 of the Controlled Drugs and Substances Act for all persons medically approved under the Narcotic Control Regulations C.R.C., c. 1041 (NCR), the MMAR or the MMPR, including those patients who have a caregiver ‘person responsible’ for them designated to produce for them, including an exemption for that caregiver ‘person responsible’ designated producer, pending trial of the merits of the action or such further Order of the court as may be necessary;
or, alternatively
2. An interlocutory exemption/injunction preserving the provisions of the MMAR relating to personal production, possession, production location and storage, by a patient or designated caregiver ‘person responsible for the patient’ and related ancillary provisions, and if necessary, limiting the applicability of certain provisions of the MMPR to such patients or designated caregivers that are inconsistent with their s. 7 constitutional right under the Charter pending the decision of this Court on the merits of this action.
Or alternatively, and together with
3. An interim/interlocutory order in the nature of mandamus to compel the Defendant to process all applications, renewals and modifications to any licences pursuant to the MMAR in accordance with all of its provisions (other than those challenged as unconstitutional herein), notwithstanding ss.230, 233-234, 237-238, 240-243 of the MMPR relating to applications under the MMAR after September 30th, 2013 as reflected in the amended MMAR sections 41-48.
And such further and other relief as the court deems appropriate and just in all of the circumstances.
ISSUES
[66] The issues are as follows:
A. Have the Applicants met the requirements for an interlocutory injunction?
B. Given the Applicants meet the requirements for an interlocutory injunction, what is the appropriate relief to grant?
i. Should the Applicants be granted either an interim constitutional exemption from the CDSA, or alternatively an interlocutory exemption/injunction preserving the MMAR, together with an Order in the nature of mandamus to compel continuation of the program, pending trial?
ii. Ought the Applicants be exempt from the undertaking requirement in subsection 373(2) of the Rules?
ANALYSIS
A. Have the Applicants Met the Requirements for an Interlocutory Injunction?
[67] The parties agree that the test for obtaining injunctive relief is the tri-partite test established in Manitoba (Attorney General) v Metropolitan Stores, (MTS) Ltd, [1987] 1 SCR 110 at paras 33-36 [Metropolitan Stores] and affirmed in RJR-MacDonald Inc v Canada (Attorney General), [1994] 1 SCR 311 at para 43 [RJR-MacDonald].
[68] The Applicants argue that it is well-established that this test may apply in the context of constitutional litigation. In particular, the Applicants notes that there is no presumption that legislation is constitutional, and for a court to insist that all legislation is enforced until it is struck down might undermine the spirit of the Charter and encourage a government to unduly prolong final resolution of the dispute at issue (RJR-MacDonald at para 39). In addition, the Applicants specify that injunctions are available to rectify invalid legislation, as is the case here, not just for prohibited conduct (Khadr v Canada, 2005 FC 1076).
[69] The Respondent argues that courts have held that interlocutory injunctive relief against the crown should be exercised sparingly (Snuneymuxw First Nation v British Columbia, 2004 BCSC 205 at para 69), as it effectively usurps the legislative and executive roles of government.
I. Is There a Serious Issue to be Tried?
[70] Based on the evidence before me, I find that the Applicants have established a serious issue to be tried.
[71] The decision in RJR-MacDonald, describes the first step of the tri-partite test at paras 49-50:
49 What then are the indicators of "a serious question to be tried"? There are no specific requirements which must be met in order to satisfy this test. The threshold is a low one. The judge on the application must make a preliminary assessment of the merits of the case (…)
50 Once satisfied that the application is neither vexatious nor frivolous, the motions judge should proceed to consider the second and third tests, even if of the opinion that the plaintiff is unlikely to succeed at trial. A prolonged examination of the merits is generally neither necessary nor desirable.
[72] RJR-MacDonald at para 48 points out the particular difficulty in conducting a detailed analysis at the interlocutory stage of Charter litigation:
…Furthermore, the complex nature of most constitutional rights means that a motions court will rarely have the time to engage in the requisite extensive analysis of the merits of the applicant's claim. This is true of any application for interlocutory relief whether or not a trial has been conducted (…)
[73] The Respondent concedes that the Applicants have satisfied this prong of the test. However, the Respondent reserves the right to contest the merits of the Applicants’ claims at trial – in particular, the Respondent argues that there is no right to a particular drug of choice where reasonable alternatives are available, nor any economic right to low cost or subsidized medication (Gosselin v Quebec (Attorney General), [2002] 4 SCR 429 at paras 82-83).
Analysis
[74] The Applicants’ affidavits establish that the section 7 liberty interests of the Applicants may be infringed given the possession offences of the CDSA, should they continue to produce marihuana as per Parker at para 92. Their liberty interest may also be infringed by virtue of their right to make fundamental life choices regarding their health (Parker at para 92), as several of the affiants testified to their concern regarding the effectiveness and safety of the marihuana offered by LPs. The Court in Parker at para 107 also held that the state action which has the likely effect of impairing a person’s health by forcing them to chose between healthcare and imprisonment, engages the section 7 right to security of the person. Here, several affiants testified to a similar effect. While these claims may not succeed at trial, they are not frivolous or vexatious. Similarly, the Applicants have a basis to claim that there is a serious issue in that the risk to their security and/or liberty interest is not in accordance with the principles of fundamental justice.
II. Are the Applicants likely to suffer irreparable harm?
[75] The Applicants rely on RJR-MacDonald, at paras 58-59, to define the second stage of the tri-partite test (para 58 affirmed in Human Rights Institute of Canada v Canada (Minister of Public Works and Government Services), [2000] 1 FC 475 at para 13):
58 At this stage the only issue to be decided is whether a refusal to grant relief could so adversely affect the applicants' own interests that the harm could not be remedied if the eventual decision on the merits does not accord with the result of the interlocutory application.
59 “Irreparable” refers to the nature of the harm suffered rather than its magnitude. It is harm which either cannot be quantified in monetary terms or which cannot be cured, usually because one party cannot collect damages from the other (…)
[76] In El-Timani v Canada Life Insurance Co, [2001] OJ No 2648 at para 9, the court recognized that “impoverishment, social stigma and the loss of dignity associated with severe poverty can constitute irreparable harm…the loss of enjoyment of life resulting from a subsistence level existence pending trial is not calculable in money.” In Elsipogtog First Nation v Canada (Attorney General), 2012 FC 387 at para 79 [Elsipogtog (FC)], (upheld on appeal in Elsipogtog v Canada (Attorney General), 2012 FCA 312 at paras 37-38) [Elsipogtog (FCA)]) the court also held that sudden poverty could lead to emotional and psychological stress that could amount to irreparable harm for some individuals, and also that harm of this nature should not be taken lightly. Similarly, in Ausman v Equitable Life Insurance Co of Canada, [2002] OJ No 3066 at para 52 [Ausman], the court found that “The long term effect of the loss of security and the impoverished lifestyle constitutes more than the loss of money. It constitutes irreparable harm.”
[77] In this case, the Applicants argues that they will suffer irreparable harm in the form of loss of enjoyment of life and avoidable suffering because of the failure of the MMPR to accommodate individual patients of meagre means who:
A. Cannot afford the rate charged by licensed providers;
B. Will no longer be able to produce their own medicine at an affordable cost;
C. Will be unable to ensure a sufficient supply of safe, high-quality product of the most suitable type for each patient’s needs; and
D. Will no longer be able to purchase forms of marihuana other than “dried marihuana” which have proven most effective at treating their respective particular illnesses.
[78] It is conceded that an increase in the cost of marihuana alone is not a basis to find irreparable harm. Rather, the cost of marihuana must be such that it puts the Applicants in a position where they are either unable to reasonably access the marihuana necessary to meet their medical needs, be otherwise severely impoverished, or endanger their liberty by forcing them to rely on the illicit market or continue personal production.
[79] The Applicants also argue that harm is more “irreparable” in Charter cases because of the particular difficulty of receiving damages in Charter cases (Mackin v New Brunswick (Minister of Finance); Rice v New Brunswick, [2002] 1 SCR 405 at paras 78-80 [Mackin]; 143471 Canada Inc v Quebec (Attorney General); Tabah v Quebec (Attorney General), [1994] 2 SCR 339).
[80] The Respondent argues that the Applicants have failed to establish that they will suffer irreparable harm because they have only offered speculative evidence as to the impact of the MMPR (PD v British Columbia, 2010 BCSC 290 at para 130). Irreparable harm must not simply be “likely” to occur (Canada (Attorney General) v United States Steel Corp, 2010 FCA 200 at para 7; International Longshore and Warehouse Union, Canada v Canada (Attorney General), 2008 FCA 3 at para 25 [International Longshore]), nor can general assertions establish irreparable harm (Gateway City Church v Canada (Minister of National Revenue, 2013 FCA 126 at paras 15, 18). The Respondent argues that this requirement arises in the context of constitutional litigation as well (International Longshore; Groupe Archambault Inc v CMRRA/SODRAC Inc, 2005 FCA 330 at para